Advertisement

Noninvasive Markers of Liver Injury and Fibrosis

  • Jenny O. Smith
  • Richard K. Sterling
Chapter

Abstract

With the increasing use of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) management and the subsequent decline in morbidity and mortality secondary to opportunistic infections, greater attention is being paid to the natural history of hepatitis C virus (HCV) among HIV–HCV coinfected patients. Graham et al.

Keywords

Human Immunodeficiency Virus Single Photon Emission Compute Tomography Hyaluronic Acid Positive Predictive Value Negative Predictive Value 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Salmon-Ceron D, Lewden C, Morlat D, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42(6):799–805.PubMedCrossRefGoogle Scholar
  3. 3.
    Schlichting P, Fauerholdt L, Christensen E, et al. Clinical relevance of restrictive morphological criteria for the diagnosis of cirrhosis in liver biopsies. Liver. 1981;1(1):56–61.PubMedGoogle Scholar
  4. 4.
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Engl J Med. 2001;344(7):495–500.PubMedCrossRefGoogle Scholar
  5. 5.
    Sterling RK. Role of liver biopsy in the evaluation of hepatitis C virus infection in HIV coinfection. Clin Infect Dis. 2005;40 Suppl 5:S270–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124(1):97–104.PubMedCrossRefGoogle Scholar
  8. 8.
    Froehlich F, Lamy O, Fried M, et al. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci. 1993;38(8):1480–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol. 1999;5(4):301–4.PubMedGoogle Scholar
  10. 10.
    Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology. 1996;23(5):1079–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med. 1979;139(6):667–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J. 1992;68(806):964–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr. 2003;32(1):30–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Pol S, Hepatitis C. virus and human immunodeficiency virus co-infection. Gastroenterol Clin Biol. 2001;25(4 Suppl):B152–6.PubMedGoogle Scholar
  15. 15.
    Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology. 2001;34(5):1000–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182(6):1595–601.PubMedCrossRefGoogle Scholar
  17. 17.
    Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus. J Acquir Immune Defic Syndr. 2006;41(1):63–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Barreiro P, Rodriguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis c. J Infect Dis. 2007;195(7):973–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40(5):538–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Snyder N, Gajula L, Xiao SY, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40(6):535–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Yu ML, Lin SM, Lee CM, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology. 2006;44(5):1086–97.PubMedCrossRefGoogle Scholar
  23. 23.
    Snyder N, Nguyen A, Gajula L, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chem Acta. 2007;381(2):119–23.CrossRefGoogle Scholar
  24. 24.
    Al-Mohri H, Cooper C, Murphy T, et al. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med. 2005;6(6):375–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, et al. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int. 2008;28(4):486–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Shastry L, Wilson T, Lascher S, et al. The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients. AIDS. 2007;21(18):2541–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Chrysanthos NV, Papatheodoridis GV, Savvas S, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol. 2006;18(4):389–96.PubMedCrossRefGoogle Scholar
  28. 28.
    Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986–92.PubMedGoogle Scholar
  29. 29.
    Macías J, Girón-González JA, González-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 2006;55(3):409–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005;43:78–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Berenguer J, Bellón JM, Miralles P, et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat. 2007;14(12):859–69.PubMedGoogle Scholar
  33. 33.
    Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Chlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17:721–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Larrousse M, Laguno M, Segarra M, et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2007;46(3):304–11.PubMedCrossRefGoogle Scholar
  35. 35.
    Resino S, Micheloud D, Miralles P, et al. Diagnosis of advanced fibrosis in hiv and hepatitis c virus-coinfected patients via a new noninvasive index: The hgm-3 index. HIV Med. 2010;11(1):64–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Sanvisens A, Serra I, Tural C, et al. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis c virus and human immunodeficiency virus coinfection. J Viral Hepat. 2009;16(7):513–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14(5):360–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Gómez-Domínguez E, Mendoza J, Rubio S, et al. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther. 2006;24(3):513–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007;46(4):628–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Ogawa E, Furusyo N, Toyoda K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res. 2007;37(12):1002–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Takeda T, Yasuda T, Nakayama Y, et al. Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. World J Gastroenterol. 2006;12(48):7768–73.PubMedGoogle Scholar
  43. 43.
    Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis c virus infection or HIV-hepatitis c virus coinfection. Clin Infect Dis. 2009;48(7):963–72.PubMedCrossRefGoogle Scholar
  45. 45.
    Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2007;45(8):969–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Macias J, Recio Eva, Vispo E, et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in hiv/hcv co-infected patients. J Hepatol. 2009;49(6):916–22.CrossRefGoogle Scholar
  47. 47.
    Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828–35.PubMedGoogle Scholar
  48. 48.
    Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastrography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40.PubMedCrossRefGoogle Scholar
  49. 49.
    Shiramizu B, Theodore D, Bassett R, et al. Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 2003;33(3):329–35.PubMedCrossRefGoogle Scholar
  50. 50.
    de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/Hepatitis C virus coinfected patients. J Acquir Immune Defic Syndr. 2006;41:175–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Masaki N, Imamura M, Kikuchi Y, et al. Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus. Hepatol Res. 2006;35(2):135–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Sanchez-Conde M, Montes-Ramirez, ML, Miralles P et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in hiv/hepatitis c virus-coinfected patients and correlation with noninvasive serum markers. Journal of viral hepatitis 2009 Sept 2. [Epub ahead of print]Google Scholar
  53. 53.
    Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with hiv/hepatitis c coinfection. HIV Clin Trials. 2008;9(1):43–51.PubMedCrossRefGoogle Scholar
  54. 54.
    Maor Y, Bashari D, Kenet G, et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia. 2006;12(4):372–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Cacoub P, Carrat F, Bédossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study–ANRS HC02. J Hepatol. 2008;48(5):765–73.PubMedCrossRefGoogle Scholar
  56. 56.
    Loko M-A et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV–HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol. 2008;103(8):1973–80.PubMedCrossRefGoogle Scholar
  57. 57.
    Tural C, Tor J, Sanvisens A, et al. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis c virus. Clin Gastro and Hep. 2009;7:339–45.CrossRefGoogle Scholar
  58. 58.
    Macias J, Gonzalez J, Ortega E et al. Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. HIV Med 2010 Feb 17. [Epub ahead of print]Google Scholar
  59. 59.
    Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a non-invasive mark. J Acquir Immune Defic Syndr. 2007;44(4):463–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Jung HS, Kim YS, Kwon OS, et al. Usefulness of liver stiffness measurement for predicting the presence of esophageal varices in the patients with liver cirrhosis. Korean J Hepatol. 2008;14(3):342–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Nunes D, Fleming C, Offner G et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastro 2010 Feb 23. [Epub ahead of print]Google Scholar
  62. 62.
    Smith JO, Sterling RK. Systematic review: noninvasive models of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009;30(6):557–76.PubMedCrossRefGoogle Scholar
  63. 63.
    Shire NJ, Rao MB, Succop P, et al. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol. 2009;7:471–80.PubMedCrossRefGoogle Scholar
  64. 64.
    Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009;29(10):1507–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Virginia Commonwealth University Medical Center/Medical College of VirginiaRichmondUSA
  2. 2.Virginia Commonwealth University Medical Center/Medical College of VirginiaRichmondUSA

Personalised recommendations